‌

US Patent 11524949 Degraders and Degrons for targeted protein degradation

Patent 11524949 was granted and assigned to C4 Therapeutics on December, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

C4 Therapeutics

0

Current Assignee

C4 Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Christopher G. Nasveschuk0

Minsheng He0

Kiel Lazarski0

James A. Henderson0

Andrew J. Phillips0

Date of Patent

December 13, 2022

0

Patent Application Number

168744750

Date Filed

May 14, 2020

0

Patent Citations

US Patent 10646575 Heterocyclic degronimers for target protein degradation

US Patent 10351568 Compositions and methods for enhancing proteasome activity

US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation

US Patent 10905768 Heterocyclic degronimers for target protein degradation

US Patent 10660968 Spirocyclic degronimers for target protein degradation

0

Patent Citations Received

0

US Patent 11802131 Glutarimides for medical treatment

Patent Primary Examiner

Noble E Jarrell

0

CPC Code

0

0

0

0

Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11524949 Degraders and Degrons for targeted protein degradation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.